Mink Therapeutics, Inc. quarterly report, Q2 FY2022

MiNK Therapeutics, Inc. — Q2 2022 Form 10-Q

Reporting period: Three and six months ended June 30, 2022; balance-sheet comparisons are with December 31, 2021. MiNK is a clinical-stage biopharmaceutical company developing allogeneic iNKT cell therapies. The filing reports no revenue.

Financial performance and liquidity

Metric	Q2 2022	Q2 2021	Six months 2022	Six months 2021
Research and development expense	$5.88m	$3.58m	$11.15m	$6.68m
General and administrative expense	$1.82m	$0.87m	$3.92m	$1.46m
Net loss	$6.11m	$6.34m	$13.89m	$10.18m
Basic and diluted loss per share	$0.18	$0.26	$0.41	$0.42
Operating cash used	Not separately stated	Not separately stated	$8.82m	$7.63m

Q2 operating loss was $7.70m versus $5.61m; six-month operating loss was $15.07m versus $8.62m.
Cash and cash equivalents were $29.85m at June 30, down from $38.89m at year-end 2021. Six-month net cash decrease was $9.04m.
Total current assets were $30.33m and current liabilities $17.43m; total assets were $31.12m and stockholders’ equity $13.69m. Due to related parties was $7.59m.
The company reported no outstanding convertible note at quarter-end; the Agenus note converted into MiNK common stock in October 2021. No other borrowing or debt balance is clearly identified in the filing text.
Management stated that quarter-end cash was expected to fund liquidity needs for more than one year from issuance of the financial statements. No revenue or profit margins are reported.

Material changes and unusual items

Year-over-year expense growth reflected clinical-trial advancement, increased preclinical work, manufacturing internalization, personnel costs, stock-based compensation, and higher professional fees.
Other income included a $2.7m gain from reducing the liability associated with a Walloon Region research-program advance. This gain helped lower reported net loss; it was not operating revenue.
The Walloon Region obtained a default judgment seeking approximately $2.2m repayment. MiNK retained that amount as a current liability and said it was evaluating options to challenge or resolve the judgment.
Share-based compensation was $1.59m for the first half of 2022, versus $0.69m a year earlier.

Outlook, programs, and risks

Management expects operating losses and negative cash flows to continue. It may seek funding through collaborations, out-licensing or partnerships, debt, or equity financing; additional equity could dilute shareholders.
MiNK said it had commenced a Phase 1 AGENT-797 multiple-myeloma trial and expected to report data in Q4 2022. It also described a Phase 1 solid-tumor trial, with preliminary readouts expected in 2022, and an intention to initiate a GvHD Phase 1 study in 2022. These are stated expectations, not assured outcomes.
Two engineered iNKT programs—BCMA-CAR-iNKT and stromal-targeting CAR-iNKT—were in preclinical development; the company said it initiated IND filings in 2022.
MiNK reported internal cGMP production of AGENT-797 and expansion capacity it said could treat more than 700,000 patients per year. It also said the viral ARDS program was selectable for DARPA funding, with contract negotiations underway.
Key risks include early-stage clinical evidence, trial safety and efficacy, enrollment and regulatory uncertainty, manufacturing complexity, financing needs, reliance on third parties and Agenus, and intellectual-property rights. The filing said there were no material changes to the risk factors in its 2021 Form 10-K.

Important facts for investors to verify

Subsequent AGENT-797 trial progress and whether the anticipated data milestones were achieved.
Cash consumption and whether cash remains sufficient for more than one year as development spending continues.
Outcome and potential financial impact of the Walloon Region judgment and repayment dispute.
Terms, costs, and governance implications of ongoing related-party services and reliance on Agenus.
Any DARPA award or contract, and the timing and funding needs of planned clinical and engineered-cell programs.